Claims
- 1. A synthetic translational regulatory element, comprising at least one oligonucleotide consisting of about 6 to 125 ribonucleotides, or a deoxyribonucleotide sequence encoding said oligonucleotide,
wherein said oligonucleotide has a translational regulatory activity selected from translational enhancing activity, translational inhibitory activity, internal ribosome entry site (IRES) activity and a combination thereof, and wherein the synthetic translational regulatory element has translational regulatory activity in a eukaryotic cell.
- 2. The synthetic translational regulatory element of claim 1, wherein said oligonucleotide consists of about 8 to 100 ribonucleotides.
- 3. The synthetic translational regulatory element of claim 1, wherein said oligonucleotide consists of about 9 to 50 ribonucleotides.
- 4. The synthetic translational regulatory element of claim 1, wherein said oligonucleotide is encoded by a nucleotide sequence selected from any of SEQ ID NOS: 42 to 46, 49, 50, 52, and 89 to 160.
- 5. The synthetic translational regulatory element of claim 1, comprising at least two of said oligonucleotides,
wherein the at least two oligonucleotides are operatively linked to each other, and wherein each of the at least two oligonucleotides independently is the same or different from each other.
- 6. The synthetic translational regulatory element of claim 5, wherein each of the at least two oligonucleotides is encoded by a nucleotide sequence selected from any of SEQ ID NOS: 42 to 46, 49, 50, 52, and 89 to 160.
- 7. The synthetic translational regulatory element of claim 5, comprising five of said oligonucleotides, which are operatively linked to each other.
- 8. The synthetic translational regulatory element of claim 5, comprising ten of said oligonucleotides, which are operatively linked to each other.
- 9. The synthetic translational regulatory element of claim 5, comprising about 2 to 75 of said oligonucleotides, which are operatively linked to each other.
- 10. The synthetic translational regulatory element of claim 5, comprising about 10 to 50 of said oligonucleotides, which are operatively linked to each other.
- 11. The synthetic translational regulatory element of claim 5, wherein each of said at least two oligonucleotides is separated from each other by a spacer nucleotide sequence, wherein said spacer nucleotide sequence consists of about 1 to 100 ribonucleotides.
- 12. The synthetic translational regulatory element of claim 5, which is encoded by a nucleotide sequence selected from any of SEQ ID NOS: 53 to 88.
- 13. The synthetic translational regulatory element of claim 1, which has IRES activity.
- 14. The synthetic translational regulatory element of claim 1, which has translational enhancing activity.
- 15. The synthetic translational regulatory element of claim 1, wherein said oligonucleotide is complementary to an oligonucleotide sequence of a ribosomal RNA.
- 16. The synthetic translational regulatory element of claim 15, wherein said oligonucleotide is derived from an oligonucleotide encoded by any of SEQ ID NOS: 2, 30, 32, 34, 36, 38, 40 and 50.
- 17. A vector, comprising the synthetic translational regulatory element of claim 1.
- 18. The vector of claim 17, which is an expression vector.
- 19. The expression vector of claim 18, which comprises a translation initiation site, wherein the translational regulatory element has translational enhancing activity.
- 20. The expression vector of claim 19, further comprising a translation start codon operatively linked to the translation initiation site.
- 21. The expression vector of claim 19, further comprising an expressible polynucleotide,
wherein the translational regulatory element is operatively linked to the expressible polynucleotide, and wherein the translational regulatory element has translational enhancing activity or IRES activity.
- 22. The expression vector of claim 21, wherein the expressible polynucleotide comprises at least one cistron.
- 23. The expression vector of claim 22, wherein the expressible polynucleotide is polycistronic.
- 24. A host cell containing the synthetic translational regulatory element of claim 1.
- 25. An isolated translational regulatory element, comprising at least one 5′ untranslated region (5′ UTR) of a eukaryotic messenger RNA (mRNA) or an oligonucleotide portion thereof, or a deoxyribonucleotide sequence encoding said 5′ UTR or oligonucleotide portion thereof,
wherein said 5′ UTR or oligonucleotide portion thereof has an activity selected from translational enhancing activity, internal ribosome entry site (IRES) activity, translational inhibitory activity, and a combination thereof, and wherein said translational regulatory element has translational regulatory activity in a eukaryotic cell.
- 26. The isolated translational regulatory element of claim 25,
wherein said 5′ UTR is encoded by a nucleotide sequence selected from any of SEQ ID NOS: 1, 23 to 29, 161, 162, and 164, and wherein said 5′ UTR or oligonucleotide portion thereof has an activity selected from translational enhancing activity and IRES activity.
- 27. The isolated translational regulatory element of claim 26, wherein said oligonucleotide portion is encoded by a nucleotide sequence selected from any of nucleotides 1 to 40, 1 to 81, 1 to 120, 41 to 81, 14 to 196, 80 to 120, 80 to 196, 120, to 166, and 120 to 196 of SEQ ID NO: 1.
- 28. The isolated translational regulatory element of claim 26, wherein said oligonucleotide portion is encoded by SEQ ID NO: 2.
- 29. The isolated translational regulatory element of claim 28, wherein said oligonucleotide portion encoded by SEQ ID NO: 2 is linked at its 5′ end or 3′ end or both 5′ and 3′ ends to a spacer nucleotide sequence, wherein said spacer nucleotides sequence consists of about 1 to 100 ribonucleotides.
- 30. The isolated translational regulatory element of claim 29, which is encoded by a nucleotide sequence selected from SEQ ID NOS: 4, 5, 12, and 20 to 22.
- 31. The isolated translational regulatory element of claim 25, comprising at least two 5′ UTRs or oligonucleotide portions thereof,
wherein the at least two 5′ UTRs or oligonucleotide portions thereof are operatively linked to each other, and wherein each of the at least two 5′ UTRs or oligonucleotide portions thereof independently is the same or different from each other.
- 32. The isolated translational regulatory element of claim 31, comprising at least two oligonucleotide portions encoded by SEQ ID NO: 2, which are operatively linked to each other.
- 33. The isolated translational regulatory element of claim 31, comprising five oligonucleotide portions encoded by SEQ ID NO: 2, which are operatively linked to each other.
- 34. The isolated translational regulatory element of claim 31, comprising ten oligonucleotide portions encoded by SEQ ID NO: 2, which are operatively linked to each other.
- 35. The synthetic translational regulatory element of claim 31, comprising about 2 to 75 of said 5′ UTRs or oligonucleotide portions thereof, which are operatively linked to each other.
- 36. The synthetic translational regulatory element of claim 31, comprising about 10 to 50 of said 5′ UTRs or oligonucleotide portions thereof, which are operatively linked to each other.
- 37. The isolated translational regulatory element of claim 31, wherein each of the at least two 5′ UTRs or oligonucleotide portions thereof is separated from each other by a spacer nucleotide sequence, wherein said spacer nucleotide sequence consists of about 1 to 100 ribonucleotides.
- 38. The isolated translational regulatory element of claim 37, consisting of two oligonucleotide portions encoded by SEQ ID NO: 2.
- 39. The isolated translational regulatory element of claim 38, which is encoded by a nucleotide sequence selected from any of SEQ ID NOS: 6 to 11 and 13 to 15.
- 40. The isolated translational regulatory element of claim 26, wherein said oligonucleotide portion is encoded by a nucleotide sequence selected from any of nucleotides 1 to 250, 100 to 508, 160 to 508, 250 to 508, 375 to 508, 429 to 508, 481 to 508, and 250 to 390 of SEQ ID NO: 29.
- 41. The isolated translational regulatory element of claim 26, wherein said oligonucleotide portion is encoded by a nucleotide sequence selected from any of SEQ ID NOS: 165 to 169, 171 to 176, and 182 to 190.
- 42. The isolated translational regulatory element of claim 26, wherein said oligonucleotide portion is encoded by a nucleotide sequence selected from SEQ ID NOS: 191 and 192.
- 43. The isolated translational regulatory element of claim 25,
wherein said 5′ UTR is encoded by a nucleotide sequence selected from any of SEQ ID NOS: 1, 23 to 29, 161, 162, and 164, and wherein said oligonucleotide portion thereof has translational inhibitory activity.
- 44. The isolated translational regulatory element of claim 43, wherein said oligonucleotide portion is encoded by a nucleotide sequence selected from nucleotides 120 to 196 and 167 to 196 of SEQ ID NO: 1.
- 45. The isolated translational regulatory element of claim 43, wherein said oligonucleotide portion is encoded by a nucleotide sequence selected from nucleotides 1 to 100 and 100 to 160 of SEQ ID NO: 29.
- 46. The isolated translational regulatory element of claim 43, wherein said oligonucleotide portion is encoded by a nucleotide sequence selected from SEQ ID NO: 193 and SEQ ID NO: 194.
- 47. The isolated translational regulatory element of claim 25, wherein said 5′ UTR or oligonucleotide portion thereof is complementary to an oligonucleotide sequence of a ribosomal RNA.
- 48. The isolated translational regulatory element of claim 47, wherein said oligonucleotide portion is encoded by any of SEQ ID NOS: 2, 30, 32, 34, 36, 38, 40 and 50.
- 49. A vector, comprising the translational regulatory element of claim 25.
- 50. The vector of claim 49, which is an expression vector.
- 51. The expression vector of claim 49, further comprising an expressible polynucleotide,
wherein the translational regulatory element is operatively linked to the expressible polynucleotide, and wherein the translational regulatory element has transcriptional enhancing activity or IRES activity.
- 52. A host cell containing the translational regulatory element of claim 25.
- 53. A kit, comprising the synthetic translational regulatory element of claim 1.
- 54. The kit of claim 53, comprising a plurality of synthetic translational regulatory elements, which are the same as or different from each other.
- 55. The kit of claim 54, wherein each of the synthetic translational regulatory elements in the plurality comprises a flanking sequence independently at a 5′ end or a 3′ end or both 5′ and 3′ ends, and
wherein the flanking sequences provide a means to operatively link two or more synthetic translational regulatory elements in the plurality to each other.
- 56. A recombinant nucleic acid molecule, comprising the synthetic translational regulatory element of claim 1 operatively linked to an expressible polynucleotide.
- 57. The recombinant nucleic acid molecule of claim 56, wherein the expressible polynucleotide comprises a cistron, and wherein the synthetic translational regulatory element has translational enhancing activity or IRES activity.
- 58. The recombinant nucleic acid molecule of claim 56, wherein the expressible polynucleotide comprises, in operative linkage in a 5′ to 3′ orientation, a first cistron, a spacer nucleotide sequence, and a second cistron,
wherein the synthetic translational regulatory element is has IRES activity, and wherein the synthetic translational regulatory element is operatively linked to the second cistron.
- 59. The recombinant nucleic acid molecule of claim 56, wherein the synthetic translational regulatory element comprises at least two operatively linked oligonucleotides having translational regulatory activity.
- 60. The recombinant nucleic acid molecule of claim 56, wherein the expressible polynucleotide encodes at least one polypeptide.
- 61. The recombinant nucleic acid molecule of claim 60, wherein the at least one polypeptide is an enzyme.
- 62. The recombinant nucleic acid molecule of claim 61, wherein the enzyme is selected from β-galactosidase, β-glucuronidase, luciferase, alkaline phosphatase, glutathione S-transferase, chloramphenicol acetyltransferase, guanine xanthine phosphoribosyltransferase, and neomycin phosphotransferase.
- 63. The recombinant nucleic acid molecule of claim 60, wherein the at least one polypeptide is selected from a viral polypeptide and a bacterial polypeptide.
- 64. The recombinant nucleic acid molecule of claim 60, wherein at least on e the polypeptide comprises an epitope expressed by a pathogenic organism.
- 65. The recombinant nucleic acid molecule of claim 60, wherein the at least one polypeptide is selected from a growth factor, a hormone and a receptor for a growth factor or a hormone.
- 66. The recombinant nucleic acid molecule of claim 60, wherein the expressible polynucleotide encodes two polypeptides.
- 67. A method of producing a genetically modified cell that exhibits altered expression of a polypeptide, the method comprising introducing a synthetic translational regulatory element of claim 1 into a cell, whereby the synthetic translational regulatory element operatively linked to a nucleotide sequence encoding a polypeptide, thereby producing a genetically modified cell that exhibits altered expression of a polypeptide.
- 68. The method of claim 67, wherein the synthetic translational regulatory element is operatively linked to the nucleotide sequence prior to introducing the synthetic translational regulatory element into the cell, wherein the synthetic translational regulatory element has translational enhancing activity or IRES activity.
- 69. The method of claim 67, wherein the polypeptide is a reporter polypeptide.
- 70. The method of claim 67, wherein the polypeptide is a toxin.
- 71. The method of claim 67, wherein the polypeptide is a therapeutic agent.
- 72. The method of claim 66, wherein the synthetic translational regulatory element is stably maintained in the cell.
- 73. The method of claim 66, wherein the synthetic translational regulatory element is integrated in the cell genome.
- 74. The method of claim 73, wherein the nucleotide sequence is a sequence of an endogenous gene in the cell genome.
- 75. The method of claim 73, wherein the synthetic translational regulatory element has translational inhibitory activity.
- 76. The method of claim 73, wherein the synthetic translational regulatory element has translational enhancing activity or IRES activity
- 77. A genetically modified eukaryotic cell produced by the method of claim 73.
- 78. A transgenic non-human eukaryotic organism, comprising the genetically modified cell of claim 77.
- 79. A cell or tissue obtained from the transgenic non-human eukaryotic organism of claim 78.
- 80. A cDNA or genomic DNA library prepared from the transgenic non-human eukaryotic organism of claim 78, or from a cell or tissue obtained from said transgenic non-human eukaryotic organism.
- 81. A method of altering translational activity in a eukaryotic cell, the method comprising introducing into the cell a synthetic translational regulatory element of claim 1, whereby the synthetic translational regulatory element interacts with a translation regulatory factor in the cell, thereby altering translational activity in the eukaryotic cell.
- 82. A method of altering translational activity in a eukaryotic cell, the method comprising introducing into the cell an isolated translational regulatory element of claim 25, whereby the isolated translational regulatory element interacts with a translation regulatory factor in the cell, thereby altering translational activity in the eukaryotic cell.
- 83. The method of claim 82, wherein the isolated translational regulatory element comprises an isolated translational regulatory element of claim 25, whereby translational activity in the cell is decreased.
- 84. The method of claim 83, wherein the isolated translational regulatory element comprises a synthetic translational regulatory element of claim 43, whereby translational activity in the cell is decreased.
- 85. A method of improving protein yield by a eukaryotic cell, comprising introducing into the cell a recombinant nucleic acid molecule comprising a synthetic translational regulatory element of claim 1 operatively linked to an expressible polynucleotide,
wherein the translational regulatory element has an activity selected from translational enhancing activity and IRES activity, and wherein the expressible polynucleotide is expressed in the cell.
- 86. The method of claim 85, wherein the expressible polynucleotide comprises a first cistron encoding a polypeptide that enhances protein stability or cell viability.
- 87. The method of claim 86, wherein the expressible polynucleotide further comprises a second cistron encoding a polypeptide of interest,
wherein the second cistron is operatively linked to the first cistron, and wherein the expressible polynucleotide comprises an IRES element, which is operatively linked to the first cistron or the second cistron or both.
- 88. The method of claim 86, wherein the polypeptide that enhances protein stability or cell viability is selected from a chaperone protein, a heat shock protein, a protein having anti-oxidant activity, a protease inhibitor, and a phosphatase inhibitor.
- 89. The method of claim 86, wherein the polypeptide that enhances protein stability or cell viability is selected from a caspase inhibitor, a magainin, a defensin, and a cryptdin.
- 90. The method of claim 87, wherein the translational regulatory element comprises a plurality of operatively linked oligonucleotide having translational enhancing activity or IRES activity or both.
- 91. The method of claim 85, wherein the expressible polynucleotide comprises a first cistron encoding a polypeptide that enhances transcription or translation of a polynucleotide in the cell.
- 92. The method of claim 91, wherein the expressible polynucleotide further comprises a second cistron encoding a polypeptide of interest,
wherein the second cistron is operatively linked to the first cistron, wherein the expressible polynucleotide comprises an IRES element, which is operatively linked to the first cistron or the second cistron or both, and and wherein the a polypeptide that enhances transcription or translation of a polynucleotide is a polypeptide that enhances transcription or translation of the expressible polynucleotide.
- 93. The method of claim 91, wherein the polypeptide that enhances transcription or translation of a polynucleotide in the cell is selected from a transcription factor and a translation regulatory factor.
- 94. The method of claim 93, wherein the polypeptide that enhances transcription or translation of a polynucleotide in the cell is a eukaryotic initiation factor.
- 95. A method of expressing a polypeptide in a eukaryotic cell, comprising:
a) introducing into the cell a recombinant nucleic acid molecule comprising a synthetic translational regulatory element of claim 1 operatively linked to an expressible polynucleotide, wherein the translational regulatory element has an activity selected from translational enhancing activity and IRES activity, and b) expressing the expressible polynucleotide in the cell.
- 96. The method of claim 95, wherein the expressible polynucleotide comprises a first cistron encoding a therapeutic polypeptide.
- 97. The method of claim 96, wherein the therapeutic polypeptide is selected from an immunomodulator, a neuromodulator, a hormone, a growth factor, a growth factor receptor, an apoptotic polypeptide, an anti-apoptotic polypeptide, and an antibiotic.
- 98. The method of claim 96, wherein the expressible polynucleotide further comprises a second cistron encoding a polypeptide that facilitates expression or activity of the therapeutic polypeptide,
wherein the second cistron is operatively linked to the first cistron, and wherein the expressible polynucleotide comprises an IRES element, which is operatively linked to the first cistron or the second cistron or both.
- 99. The method of claim 98, polypeptide that facilitates expression or activity of the therapeutic polypeptide is selected from a transcription factor that increases transcription of the expressible polynucleotide, a translational regulatory factor that increases translation of a polypeptide encoded by the expressible polynucleotide, a chaperone protein, a protein having anti-oxidant activity, a protease inhibitor, and a phosphatase inhibitor.
- 100. The method of claim 95, wherein introducing the expressible polynucleotide is cell is performed ex vivo or in vivo.
- 101. The method of claim 95, wherein the recombinant nucleic acid molecule is contained in a vector.
- 102. The method of claim 101, wherein the vector is a viral vector.
- 103. The method of claim 102, wherein the viral vector is selected from an adenovirus vector, an adeno-associated virus vector, and a retrovirus vector.
- 104. The method of claim 95, wherein the expressible polynucleotide encodes a reporter polypeptide.
- 105. The method of claim 104, wherein expression of the reporter polypeptide is detectable in a cell ex vivo or in vivo.
- 106. The method of claim 104, wherein expression of the reporter polypeptide provide a means to diagnose or monitor the progression of a pathologic condition.
- 107. A method of identifying a cell, comprising introducing into the cell a recombinant nucleic acid molecule comprising a synthetic translational regulatory element of claim 1 operatively linked to an expressible polynucleotide,
wherein the translational regulatory element has an activity selected from translational enhancing activity and IRES activity, and wherein the expressible polynucleotide comprises at least one cistron, which encodes a first reporter polypeptide, and wherein expression of the reporter polypeptide in the cell provides a means to identify the cell.
- 108. The method of claim 107, wherein the expressible polynucleotide further comprises a second cistron encoding a polypeptide of interest,
wherein the second cistron is operatively linked to the first cistron, and wherein the expressible polynucleotide comprises an IRES element, which is operatively linked to the first cistron or the second cistron or both.
- 109. The method of claim 108, wherein the polypeptide of interest is a second reporter polypeptide.
- 110. The method of claim 109, wherein the second reporter polypeptide is different from the first reporter polypeptide.
- 111. The method of claim 107, further comprising isolating a cell expressing a reporter polypeptide.
- 112. The method of claim 111, wherein the reporter polypeptide is a cell surface marker, and wherein isolating the cell expressing the cell surface marker comprises using an antibody that specifically binds the cell surface marker.
- 113. The method of claim 112, wherein the cell surface marker comprises a peptide tag operatively linked to a cell surface protein.
- 114. An isolated cell obtained by the method of claim 111.
Priority Claims (6)
Number |
Date |
Country |
Kind |
60178816 |
Jan 2000 |
US |
|
60186496 |
Mar 2000 |
US |
|
60207804 |
May 2000 |
US |
|
60230852 |
Sep 2000 |
US |
|
60230956 |
Sep 2000 |
US |
|
60261312 |
Jan 2001 |
US |
|
Parent Case Info
[0001] This application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Serial No. 60/230,956, filed Sep. 7, 2000; U.S. Serial No. 60/230,852, filed Sep. 7, 2000; U.S. Serial No. 60/207,804, filed May 30, 2000; U.S. Serial No. 60/186,496, filed Mar. 2, 2000; U.S. Serial No. 60/178,816, filed Jan. 28, 2000; and U.S. Serial No. ______ (attorney docket SCRIP1370), filed Jan. 12, 2001, each of which is incorporated herein by reference.
Government Interests
[0002] This invention was made in part with government support under Grant No. MCB9982574 awarded by the National Science Foundation. The government has certain rights in this invention.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/02586 |
1/26/2001 |
WO |
|